HTG Molecular Diagnostics Receives European Patent Grant Notification for Methods for Subtyping Diffuse Large B-cell Lymphoma
Lymphoma is the most common blood cancer, and DLBCL is the most common form of non‑Hodgkin’s lymphoma, accounting for up to 30 percent of newly diagnosed cases. There is no single, accepted diagnostic test for distinguishing germinal center B-cell-like (GCB) and non-GCB (for example, activated B-cell-like or
“We are pleased to receive notification of the patent grant in
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential predictive benefits of molecular subtyping. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including but not limited to, risks relating to the ability of molecular subtyping to perform as intended or expected. These and other factors are described in greater detail in our filings with the
LifeSci Advisors, LLC
Phone: (617) 430-7577
Source: HTG Molecular Diagnostics, Inc.